We are right @ our entire Hiv portfolio being lisc
Post# of 151786
(Total Views: 588)
Posted On: 02/22/2025 3:18:39 PM
We are right @ our entire Hiv portfolio being liscensed.
Dr. Sacha's work covers every aspect of Hiv with Leronlimab.
He has been funded from so many sources: NIH, AmFar, DOD, GF, Foundations, Grants, etc., etc..
GF/ViiV(GSK) are ready for human trials & given the significance, would absolutely now want full control.
Cytodyn's & Dr. Sacha's many NDA's need to be overcome:
Liscense Cytodyn's entire Hiv portfolio.
Phase 1 drugs are doing $600m+ deals. Trials/royalties included + manufacturing.
Mfgr for all LL liscense deals from there.
Cost + 10% fee.
Facility becomes a cash cow.
GF $1m grant compiles Dr. Sachas's 7-8 yrs of data we do & do not know of, while starting multiple types of trials.
BOOOM !!!
Dr. Sacha's work covers every aspect of Hiv with Leronlimab.
He has been funded from so many sources: NIH, AmFar, DOD, GF, Foundations, Grants, etc., etc..
GF/ViiV(GSK) are ready for human trials & given the significance, would absolutely now want full control.
Cytodyn's & Dr. Sacha's many NDA's need to be overcome:
Liscense Cytodyn's entire Hiv portfolio.
Phase 1 drugs are doing $600m+ deals. Trials/royalties included + manufacturing.
Mfgr for all LL liscense deals from there.
Cost + 10% fee.
Facility becomes a cash cow.
GF $1m grant compiles Dr. Sachas's 7-8 yrs of data we do & do not know of, while starting multiple types of trials.
BOOOM !!!
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼